WASHINGTON, Sept 22 (Reuters) - U.S. health regulators knew that Johnson & Johnson's (JNJ.N) McNeil unit was using a contractor to buy back potentially faulty batches of Motrin, although there was no formal agreement with the government, lawyers for the company told lawmakers.
